24 June 2021
Latham & Watkins Advises Novo Holdings on Quanta’s US$245 Million Series D Fundraising
Advising firms
Deal team
7 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Robbie McLaren Lead | Latham & Watkins LLP | Partner | corporate | London |
| Samantha Peacock | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Frances Stocks Allen | Latham & Watkins LLP | Associate | life science | Not stated |
| Sara Patel | Latham & Watkins LLP | Associate | life science | Not stated |
| Oscar Bjartell | Latham & Watkins LLP | Associate | life science | Not stated |
| Adam Ray | Latham & Watkins LLP | Associate | employment | Not stated |
| Kendall Burnett | Latham & Watkins LLP | Associate | employment | Not stated |
Stated terms
- Stated value
- USD 245m (US$245 Million)
- What the figure measures
- Fund size
- Client
- Novo HoldingsInvestor
- Counterparties
- Quanta Dialysis Technologies (Issuer)
Glenview Capital (Investor)
BlackRock (Investor)
Eldridge (Investor)
Sands Capital (Investor)
Millennium (Investor)
Monashee Investment Management LLC. (Investor)
Puhua Capital (Investor)
Segulah Medical (Investor)
Ancora (Investor)
Orlando Health (Investor)
Wellington Partners (Investor)
btov (Investor)
Seroba (Investor)
The Grands (Investor)